Paper7701344
E5531, a pure endotoxin antagonist of high potency.
Christ WJ and 9 others. Science, 1995. Cited by 245 papers, by iCite.
Cite this record
ConductScience Library. E5531, a pure endotoxin antagonist of high potency. Papers, record 7701344. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/7701344
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics20
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Endotoxins | Major topic |
| Lipid A | Major topic |
| Animals | |
| BCG Vaccine | |
| Cytokines | |
| Drug Design | |
| Escherichia coli Infections | |
| Gram-Negative Bacteria | |
| Humans | |
| In Vitro Techniques | |
| Lipopolysaccharides | |
| Macrophages | |
| Male | |
| Mice | |
| Mice, Inbred C57BL | |
| Monocytes | |
| Moxalactam | |
| Nitric Oxide | |
| Rhodobacter capsulatus | |
| Tumor Necrosis Factor-alpha |
Source PubMed
Cited by77
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 245 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42635416 | HMGB1-targeted anti-inflammatory rBox A gene therapy for viral airway infections and systemic inflammatory disease models. | mBio | 2026 | https://conductscience.org/library/papers/42635416 | PubMed |
| 40033742 | Preclinical development of the TLR4 antagonist FP12 as a drug lead targeting the HMGB1/MD-2/TLR4 axis in lethal influenza infection. | Innate Immun | 2025 | https://conductscience.org/library/papers/40033742 | PubMed |
| 38110468 | Analysis of oxidized glucosylceramide and its effects on altering gene expressions of inflammation induced by LPS in intestinal tract cell models. | Sci Rep | 2023 | https://conductscience.org/library/papers/38110468 | PubMed |
| 38033733 | Small molecule modulators of immune pattern recognition receptors. | RSC Chem Biol | 2023 | https://conductscience.org/library/papers/38033733 | PubMed |
| 35744687 | Genome Sequence and Characterization of a Xanthorhodopsin-Containing, Aerobic Anoxygenic Phototrophic Rhodobacter Species, Isolated from Mesophilic Conditions at Yellowstone National Park. | Microorganisms | 2022 | https://conductscience.org/library/papers/35744687 | PubMed |
| 34113349 | Rhodobacter azotoformans LPS (RAP99-LPS) Is a TLR4 Agonist That Inhibits Lung Metastasis and Enhances TLR3-Mediated Chemokine Expression. | Front Immunol | 2021 | https://conductscience.org/library/papers/34113349 | PubMed |
| 33376308 | Preventive Effect of Lactobacillus acidophilus XY27 on DSS-Induced Ulcerative Colitis in Mice. | Drug Des Devel Ther | 2020 | https://conductscience.org/library/papers/33376308 | PubMed |
| 33356849 | Lipid larceny: channelizing host lipids for establishing successful pathogenesis by bacteria. | Virulence | 2021 | https://conductscience.org/library/papers/33356849 | PubMed |
| 32425790 | Like Cures Like: Pharmacological Activity of Anti-Inflammatory Lipopolysaccharides From Gut Microbiome. | Front Pharmacol | 2020 | https://conductscience.org/library/papers/32425790 | PubMed |
| 31741857 | Inhibitive effect of TAK-242 on Tenon's capsule fibroblasts proliferation in rat eyes. | Int J Ophthalmol | 2019 | https://conductscience.org/library/papers/31741857 | PubMed |
| 30154796 | Bradyrhizobium Lipid A: Immunological Properties and Molecular Basis of Its Binding to the Myeloid Differentiation Protein-2/Toll-Like Receptor 4 Complex. | Front Immunol | 2018 | https://conductscience.org/library/papers/30154796 | PubMed |
| 29518316 | Dissecting the Innate Immune Recognition of Opioid Inactive Isomer (+)-Naltrexone Derived Toll-like Receptor 4 (TLR4) Antagonists. | J Chem Inf Model | 2018 | https://conductscience.org/library/papers/29518316 | PubMed |
| 28769820 | Inhibition of Toll-Like Receptor Signaling as a Promising Therapy for Inflammatory Diseases: A Journey from Molecular to Nano Therapeutics. | Front Physiol | 2017 | https://conductscience.org/library/papers/28769820 | PubMed |
| 28621828 | Progress in the synthesis and biological evaluation of lipid A and its derivatives. | Med Res Rev | 2018 | https://conductscience.org/library/papers/28621828 | PubMed |
| 26995266 | Sepsis: in search of cure. | Inflamm Res | 2016 | https://conductscience.org/library/papers/26995266 | PubMed |
| 26798659 | Balancing Innate Immunity and Inflammatory State via Modulation of Neutrophil Function: A Novel Strategy to Fight Sepsis. | J Immunol Res | 2015 | https://conductscience.org/library/papers/26798659 | PubMed |
| 26771196 | In Search of a Cure for Sepsis: Taming the Monster in Critical Care Medicine. | J Innate Immun | 2016 | https://conductscience.org/library/papers/26771196 | PubMed |
| 26535075 | Lipid A as a Drug Target and Therapeutic Molecule. | Biomol Ther (Seoul) | 2015 | https://conductscience.org/library/papers/26535075 | PubMed |
| 25620999 | Novel drugs targeting Toll-like receptors for antiviral therapy. | Future Virol | 2014 | https://conductscience.org/library/papers/25620999 | PubMed |
| 25553892 | Characterization of TRIF selectivity in the AGP class of lipid A mimetics: role of secondary lipid chains. | Bioorg Med Chem Lett | 2015 | https://conductscience.org/library/papers/25553892 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- References
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/7701344
GET https://conductscience.org/api/papers/v1/7701344/cited_by?page=2